



Motor dysfunction in mild cognitive impairment as tested by kinematic analysis and transcranial magnetic stimulation [☆]



Donato Colella ^a, Andrea Guerra ^b, Giulia Paparella ^b, Ettore Cioffi ^a, Antonella Di Vita ^c,
Alessandro Trebbastoni ^a, Alfredo Berardelli ^{a,b,*}, Matteo Bologna ^{a,b}

^a Department of Human Neurosciences, Sapienza University of Rome, Italy

^b IRCCS Neuromed, Pozzilli (IS), Italy

^c Department of Psychology, Sapienza University of Rome, Italy

ARTICLE INFO

Article history:

22 July 2020

16 September 2020

Accepted 24 October 2020

Available online 2 December 2020

Keywords:

Mild cognitive impairment

Movement slowness

Motor cortex

Motor control

TMS

HIGHLIGHTS

- Voluntary movement abnormalities can be observed in mild cognitive impairment (MCI).
- Abnormal rhythm during repetitive finger movements in MCI patients relates to frontal dysfunction.
- Altered voluntary movement may be an early motor feature in patients with cognitive decline.

ABSTRACT

Objective: Previous studies have demonstrated voluntary movement alterations as well as motor cortex excitability and plasticity changes in patients with mild cognitive impairment (MCI). To investigate the pathophysiology of movement abnormalities in MCI, we tested possible relationships between movement abnormalities and primary motor cortex alterations in patients.

Methods: Fourteen amnesic MCI (aMCI) patients and 16 healthy controls were studied. Cognitive assessment was performed using clinical scales. Finger tapping was recorded by a motion analysis system. Transcranial magnetic stimulation was used to test the input/output curve of motor evoked potentials, intracortical inhibition, and short-latency afferent inhibition. Primary motor cortex plasticity was probed by theta burst stimulation. We investigated correlations between movement abnormalities, clinical scores, and cortical neurophysiological parameters.

Results: MCI patients showed less rhythmic movement but no other movement abnormalities. Cortical excitability measures were normal in patients, whereas plasticity was reduced. Movement rhythm abnormalities correlated with frontal dysfunction scores.

Conclusion: Our study in MCI patients demonstrated abnormal voluntary movement and plasticity changes, with no correlation between the two. Altered rhythm correlated with frontal dysfunction.

Significance: Our results contribute to the understanding of pathophysiological mechanisms of motor impairment in MCI.

© 2020 Published by Elsevier B.V. on behalf of International Federation of Clinical Neurophysiology.

Abbreviations: AMT, active motor threshold; AD, Alzheimer's disease; aMCI, amnesic mild cognitive impairment; ANOVA, analysis of variance; BDI-II, Beck Depression Inventory; CV, coefficient of variation; EMG, electromyography; FDI, first dorsal interosseous; FAB, Frontal Assessment Battery; HCs, healthy controls; I/O, input-output; ISI, interstimulus interval; LTP, long-term potentiation; M1, primary motor cortex; MCI, mild cognitive impairment; MEPs, motor evoked potentials; MoCA, Montreal Cognitive Assessment; MT1mV = intensity required to produce MEPs of ~1 mV in size Montreal Cognitive Assessment; MDS-UPDRS, Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale; naMCI, nonamnesic mild cognitive impairment; rmANOVA, repeated-measures analysis of variance; RMT, resting motor threshold; short-interval (SICI), intracortical inhibition; SAI, short-latency afferent inhibition; SPECT, single photon emission computed tomography; SD, standard deviation; iTBS, intermittent theta burst stimulation; TMS, transcranial magnetic stimulation.

[☆] The study was conducted in laboratories of the Department of Human Neurosciences, Sapienza University of Rome, Italy.

* Corresponding author at: Department of Human Neurosciences, and IRCCS Neuromed, Sapienza University of Rome, Viale dell'Università 30, 00185 Rome, Italy.

E-mail address: alfredo.berardelli@uniroma1.it (A. Berardelli).

<https://doi.org/10.1016/j.clinph.2020.10.028>

1388-2457/© 2020 Published by Elsevier B.V. on behalf of International Federation of Clinical Neurophysiology.

1. Introduction

Mild cognitive impairment (MCI) is a condition characterized by an objective impairment in cognition that is not severe enough to require help with normal activities of daily living (Petersen, 2004; Albert et al., 2011). MCI is a heterogeneous condition that can be classified according to the type of involved cognitive domain as either amnesic (aMCI) or nonamnesic (naMCI) MCI (Petersen et al., 2014). Studies have found that patients with aMCI have a high probability of developing Alzheimer's disease (AD) (Petersen, 2004; Winblad et al., 2004).

Besides cognitive disturbances, movement studies have variably shown voluntary motor abnormalities in MCI patients, including movement slowness, altered rhythm, impaired fine motor skills, coordination abnormalities, and gait difficulties (Kluger et al., 1997; Schröder et al., 2003; Louis et al., 2005; Aggarwal et al., 2006; Camarda et al., 2007; Yan et al., 2008; Rabinowitz and Lavner, 2014; Roalf et al., 2018; Suzumura et al., 2018). However, some studies have not reported any significant movement abnormalities in MCI (Kluger et al., 1997; Goldman et al., 1999). To date, it is still unclear whether voluntary movement abnormalities in MCI patients reflect cognitive deficits (Rabinowitz and Lavner, 2014; Roalf et al., 2018; Suzumura et al., 2018; Zhang et al., 2018) or whether they are caused by neuropathological involvement of cerebral areas directly implicated in motor control, including the primary motor cortex (M1) (Orta-Salazar et al., 2019), basal ganglia (Burns et al., 2005), and parietal and frontal cortices (Nitri et al., 2000; Camarda et al., 2007; Okello et al., 2009; Chandra et al., 2019). In this regard, neurophysiological investigations using transcranial magnetic stimulation (TMS) techniques have demonstrated M1 abnormalities in MCI patients, including excitability changes, i.e. reduced short-interval intracortical inhibition (SICI) and short-latency afferent inhibition (SAI), as well as a lack of M1 plasticity (Olazarán et al., 2010; Nardone et al., 2012, 2014; Cantone et al., 2014; Trebbastoni et al., 2015; Padovani et al., 2018, 2019; Di Lorenzo et al., 2020). However, whether these M1 changes play a role in generating voluntary movement abnormalities in MCI patients is unclear.

In this study, we tested possible correlations between voluntary movement abnormalities, M1 neurophysiological parameters, clinical evaluation of cognitive functions, and demographic features of aMCI patients. For this purpose, we objectively assessed voluntary movement execution by kinematic analysis of repetitive finger movements in aMCI patients (Espay et al., 2009, 2011; Bologna et al., 2016, 2018, 2020). Namely, we measured movement amplitude and velocity (degree/s) and amplitude and velocity reduction during movement repetition. Movement rhythm was also measured (Ianssek et al., 2006; Bologna et al., 2016, 2018, 2020). Using TMS techniques, we then tested M1 excitability parameters, including resting (RMT) and active (AMT) motor thresholds, the input–output (I/O) curve of motor evoked potentials (MEPs), SICI, SAI, and M1 long-term potentiation (LTP)-like plasticity (Berardelli et al., 2008; Bologna et al., 2020). Data obtained from aMCI patients were compared with those obtained from a group of healthy controls.

2. Materials and methods

2.1. Participants

Fourteen patients with aMCI (10 males, mean age \pm 1 standard deviation (SD): 74.6 ± 5.8 years) and 16 healthy controls (HCs) (8 males, mean age: 71.1 ± 11.1 years) were enrolled in the study. All participants were right-handed, as evaluated by the Edinburgh Handedness Inventory (Oldfield, 1971). MCI diagnosis was based

on clinical criteria (Albert et al., 2011). All patients underwent laboratory blood tests and magnetic resonance imaging of the brain to exclude secondary forms of dementia, and a complete neuropsychological battery to identify the pattern of cognitive alterations. Patients with epilepsy, migraine, or other psychiatric disturbances were also excluded. Treatment with drugs potentially influencing corticospinal excitability or plasticity was discontinued at least 72 h prior to the evaluation (Ziemann et al., 2015). Patients were clinically evaluated through the Movement Disorder Society (MDS)-sponsored revision of the Unified Parkinson's Disease Rating Scale, motor section (UPDRS-III) (Antonini et al., 2013). Clinical assessment also included the Montreal Cognitive Assessment (MoCA) (Freitas et al., 2013), the Frontal Assessment Battery (FAB) (Dubois et al., 2000), and the Beck Depression Inventory (BDI-II) (Beck et al., 1961). The study conformed to the Declaration of Helsinki and international safety guidelines (Rossi et al., 2009; Rossini et al., 2015a) and was approved by the local ethics committee. All subjects provided written informed consent for their participation in the study.

2.2. Movement analysis

Subjects sat comfortably on a chair and were asked to tap their index finger repetitively on their thumb as widely and quickly as possible for 15 s with the dominant hand (finger-tapping task) (Bologna et al., 2016, 2018, 2020). Three finger-tapping trials were recorded, and movements were performed with a 60-s rest interval between trials in order to avoid fatigue. In addition, one practice trial was required before kinematic recording began in order to familiarize participants with the motor task. An optoelectronic system (SMART motion, BTS Technology, Italy) was used for kinematic measurements. Reflective markers with negligible weight and a 5-mm diameter were taped to the participant's upper limb. The three-dimensional displacement of these markers was followed by three infrared cameras (sampling rate of 120 Hz). Two markers were positioned on the tips of thumb and the index finger and 3 additional markers were placed on the hand (one on the head of the 2nd metacarpal bone, one on the base of the 2nd metacarpal bone, and one on the base of the 5th metacarpal bone). This montage allowed to determine a reference plane and mathematically eliminate possible interference of undesired movements of the hand during recordings (Bologna et al., 2016, 2018, 2020). Movement analysis was performed using specialized software (SMART Analyzer, BTS Engineering, Italy). Linear regression techniques to determine the intercept reflecting movement amplitude (degree) and velocity (degree/s) were used to quantify repetitive finger movement kinematics, as well as the slope representing amplitude and velocity decrement during movement repetition. We also used the coefficient of variation (CV), as calculated by SD/mean value of the intertap intervals, to measure movement rhythm, with higher values corresponding to lower repetitive movement regularity (the higher the CV value, the less rhythmic the movement performed) (Ianssek et al., 2006; Bologna et al., 2016, 2018, 2020).

2.3. TMS

Single- and paired-pulse TMS was provided via a Magstim BiStim² and a figure-of-eight coil delivering monophasic pulses (Magstim Company Limited, UK), to study cortical excitability. The hotspot of the right first dorsal interosseous (FDI) muscle (i.e. optimal scalp site to elicit MEPs) was identified with the TMS coil handle oriented backwards and laterally to the midline. We estimated RMT (minimum stimulus intensity producing an MEP of ≥ 50 μ V peak-to-peak amplitude in at least 50% of 10 trials with the tested muscle at rest) and AMT (minimum stimulus intensity producing an MEP of ~ 200 μ V peak-to-peak amplitude in at least 50% of 10

trials during mild isometric contraction of the tested muscle) (Rossini et al., 2015a), as well as the intensity required to produce MEPs of ~ 1 mV in size (MT_{1mV}) (Curra et al., 2002). Ten single TMS pulses at six different stimulation intensities (total of 60 pulses) ranging in 20% increments from 80–180% RMT were delivered in order to measure the I/O curve. We randomized the order of intensity to avoid hysteresis effects (Möller et al., 2009; Bologna et al., 2015). Standardized protocols were used to evaluate SICI and SAI (Kujirai et al., 1993; Tokimura et al., 2000). We tested SICI by delivering paired TMS pulses with a subthreshold conditioning stimulus at 80% AMT, an MT_{1mV} suprathreshold test stimulus, and two inter-stimulus intervals (2 and 4 ms ISIs). For SAI, we used a 0.1 ms electrical rectangular pulse (DS7 stimulator; Digitimer, UK) at the intensity inducing a painless twitch of the thumb to perform median nerve stimulation at the wrist. We set TMS intensity at MT_{1mV} , and tested two intervals between the median nerve and cortical stimulation (22 and 24 ms ISIs). SICI and SAI were evaluated in separate blocks. Fifteen trials were recorded for each ISI for both SICI and SAI. Trials were randomized with 15 single-pulse stimuli delivered at MT_{1mV} (unconditioned MEPs). SICI and SAI were expressed as a ratio (unconditioned/conditioned MEPs). The intertrial interval of MEP recordings in the I/O curve, SICI and SAI was 4.5–5.5 s.

Cortical plasticity was assessed using intermittent theta-burst stimulation (iTBS – Huang et al., 2005) delivered through a biphasic stimulator (Magstim SuperRapid; Magstim Company Limited, UK) connected to a figure-of-eight coil positioned over the hotspot. The intensity of stimulation was 80% AMT. Ten bursts of three pulses at 50 Hz were repeated at 200 ms intervals and delivered in short 2 s trains, with a pause of 8 s between consecutive trains (20 trains, 600 pulses in total) (Huang et al., 2005).

We recorded MEPs via surface electrodes with a standard belly-tendon montage. Digitimer D360 (Digitimer, UK) was used to amplify and filter (20 Hz–1 kHz) electromyographic (EMG) signals, which were then stored on a computer (5 kHz sampling rate) through an analog–digital converter AD1401 plus (Cambridge Electronic Design, UK) and analyzed offline with specialized software (Signal version 5.08, Cambridge Electronic Design, UK). We rejected trials with background EMG activity > 100 μ V in the 200 ms before TMS. The amplitude of MEPs was calculated peak-to-peak in the 20–40 ms following the TMS artifact.

2.4. Experimental design

Subjects participated in a single experimental session that included clinical evaluation and kinematic recording of finger movements. TMS assessment began with RMT, AMT, and MT_{1mV} estimation, followed by the measurement of corticospinal and intracortical excitability parameters at rest. Finally, 15 MT_{1mV} MEPs (intertrial interval 4.5–5.5 s) were recorded before (T0) and 5 (T1), 15 (T2), and 30 min (T3) after iTBS in order to assess the LTP-like plasticity of M1. Thus, the interval between motor threshold estimation and pre-iTBS baseline MEP recording was ~ 20 min.

2.5. Statistical analysis

The Mann–Whitney U test was used to evaluate possible differences in age and MoCA, FAB, BDI-II, and UPDRS-III scores between aMCI patients and HCs, while Fisher's exact test was applied to evaluate possible differences in gender distribution between groups. Unpaired t-tests were used to compare kinematic variables, motor thresholds, and the amplitude of MEPs evoked by single TMS pulses (i.e. unconditioned MEPs for SICI and SAI and MEPs before iTBS).

A repeated-measures analysis of variance (rmANOVA) with 'GROUP' (2 levels: aMCI, HC) and 'TMS intensity' (6 levels: 80%, 100%, 120%, 140%, 160%, and 180% RMT) as factors was used to

assess possible differences in the I/O curve between aMCI patients and HCs. The same analysis with 'GROUP' and 'ISI' (2 levels: 2 and 4 ms for SICI, 22 and 24 ms for SAI) was applied to compare SICI and SAI between aMCI patients and HCs. An rmANOVA with 'GROUP' and 'TIME POINT' (3 levels: T1, T2, and T3) as factors was adopted to verify possible differences in iTBS effects between groups. For this analysis, MEP amplitude recorded at T1, T2, and T3 was normalized to T0.

The Duncan test was used as a post-hoc analysis in the various rmANOVAs. We applied Greenhouse–Geisser corrections when a violation of sphericity was detected using Mauchly's test. Pearson's coefficient was used to test possible correlations between kinematic and TMS measures, whereas Spearman's rank correlation coefficient was adopted to verify possible relationships between patient clinical data and neurophysiological measures (kinematic and TMS parameters). Unless otherwise stated, results are shown as mean values ± 1 standard error of the mean. The significance level was set at $p < 0.05$ and data were analyzed using STATISTICA (TIBCO Software Inc., Palo Alto, California, US).

3. Results

3.1. Clinical and demographic data

Age ($p = 0.42$), gender distribution ($p = 0.28$), and BDI-II scores ($p = 0.55$) were comparable between aMCI patients and HCs. In contrast, MoCA (aMCI patients: 21.0 ± 3.9 vs. HCs: 25.1 ± 0.9 , $p = 0.01$) and FAB scores (aMCI patients: 14.2 ± 2.5 vs. HCs: 16.0 ± 0.4 , $p = 0.04$) were both lower in patients than in HCs. The mean ± 1 SD) of the UPDRS-III score in MCI patients was 2.8 ± 2.6 (Table 1) due to the presence of very mild impairment in finger and foot tapping (7/14 patients), rigidity of the upper limb (3/14 patients), slightly impaired posture (3/14 patients), slight postural and kinetic tremor (2/14 patients), and gait imbalance (1/14 patients). However, no patient had bradykinesia associated with rigidity or tremor that would have met the definition for parkinsonism (Postuma et al., 2015).

3.2. Movement kinematics

The analysis demonstrated altered movement rhythm in aMCI patients, as demonstrated by the higher CV values with respect to HCs (aMCI patients: 0.16 ± 0.05 , HCs: 0.11 ± 0.04 , $p < 0.01$). In contrast, the number of performed movements (aMCI patients: 45.8 ± 15.21 , HCs: 51.48 ± 13.63 , $p = 0.29$), movement amplitude (aMCI patients: 45.9 ± 13.54 degrees, HCs: 48.32 ± 15.7 degrees, $p = 0.65$), movement velocity (aMCI patients: 871.06 ± 231.62 degrees/s, HCs: 858.62 ± 232.45 degrees/s, $p = 0.88$), amplitude decrement (aMCI patients: -0.25 ± 0.28 degrees/n mov, HCs: 0.26 degrees/n mov, $p = 0.92$), and velocity decrement (aMCI patients: -5.47 ± 6.3 (degrees/s)/n mov, HCs: -3.11 ± 4.44 (degrees/s)/n mov, $p = 0.24$) were all similar between patients and HCs (Fig. 1).

3.3. TMS measures

AMT, RMT, MT_{1mV} , unconditioned MEP amplitude in SICI and SAI protocols, and MEP amplitude before iTBS did not differ between groups (Table 2). The I/O curve was also similar between aMCI patients and HCs ('GROUP': $F_{1,28} = 0.70$, $p = 0.41$; 'GROUP' x 'TMS intensity': $F_{5,140} = 1.67$, $p = 0.15$) (Fig. 2a), as was the degree of SICI ('GROUP': $F_{1,28} = 0.01$, $p = 0.92$; 'GROUP' x 'ISI': $F_{1,28} = 0.16$, $p = 0.69$) and SAI ('GROUP': $F_{1,28} = 0.59$, $p = 0.45$; 'GROUP' x 'ISI': $F_{1,28} = 1.53$, $p = 0.23$) (Fig. 2b). When comparing SICI, a significant

Table 1
Clinical-demographic characteristics of patients with mild cognitive impairment.

	Gender	Age (Years)	BDI-II	FAB	MoCA	UPDRS-III
1	F	76	19	13	24	4
2	M	85	6	16	25	5
3	M	70	8	14	17	4
4	M	69	9	17	26	0
5	F	83	13	10	19	3
6	F	72	14	18	26	0
7	M	79	2	13	17	6
8	M	70	4	16	21	0
9	M	78	7	15	22	0
10	M	73	1	10	12	0
11	M	74	5	11	20	2
12	M	77	5	15	21	7
13	M	63	11	16	20	6
14	F	75	11	14	24	2
Mean	-	74.6	8.2	14.2	21.0	2.8
SD	-	5.8	5.0	2.5	3.9	2.6

F = female; M = male; BDI –II = Beck Depression Inventory; FAB = Frontal Assessment Battery; MoCA = Montreal Cognitive Assessment; UPDRS-III = Unified Parkinson's Disease Rating Scale, part III; SD = standard deviation.

effect of the factor 'ISI' emerged ($F_{1,28} = 6.26$, $p = 0.02$), indicating lower values at ISI 2 ms than 4 ms.

When comparing the effects of iTBS between aMCI patients and HCs, rmANOVA showed a significant 'GROUP' x 'TIME POINT' interaction ($F_{2,56} = 3.87$, $p = 0.03$) and no effect of the main factor 'GROUP' ($F_{1,28} = 1.93$, $p = 0.17$). As expected, the analysis also showed a significant effect of 'TIME POINT' ($F_{2,56} = 3.20$, $p = 0.04$), indicating peak MEP facilitation after iTBS at T2. Interestingly, post-hoc analysis revealed that iTBS-induced MEP facilitation was lower in aMCI patients than in HCs at T2 ($p = 0.03$), while values at T1 ($p = 0.46$) and T3 ($p = 0.18$) were comparable between groups (Fig. 3).

3.4. Correlation analysis

We found a negative relationship between movement rhythm (CV) and FAB scores ($r = -0.68$, $p < 0.01$), meaning that a higher CV (less rhythmic movement) was associated with a lower FAB score (greater cognitive impairment). In addition, a trend toward correlation was present between movement rhythm and MoCA score ($r = -0.43$, $p = 0.11$). No relationship was found between movement rhythm and iTBS-induced MEP facilitation at T2 in patients ($r = 0.10$, $p = 0.72$), or between iTBS-induced MEP facilitation at T2 and FAB ($r = -0.05$, $p = 0.86$) or MoCA scores ($r = -0.15$, $p = 0.61$).

4. Discussion

In the present study, we examined voluntary movement execution in aMCI patients through kinematic analysis of repetitive finger tapping. We then tested whether movement abnormalities correlated with clinical cognitive scores or altered neurophysiological measures of M1. We found that finger-tapping movements in aMCI patients were characterized by less rhythmic movement (increased CV) as compared to HCs. We also found decreased synaptic M1 plasticity in aMCI patients. Movement rhythm abnormalities correlated with FAB score but not with altered M1 plasticity in aMCI patients. Our results provide evidence of motor dysfunction and insight into its possible pathophysiological mechanisms in MCI.

The less rhythmic movement observed in aMCI patients during finger-tapping execution is in line with previous studies that used computerized (though not kinematic) methods of analysis and reported increased intraindividual variability (Roalf et al., 2018)

or rhythm fluctuation during finger tapping (Suzumura et al., 2018). The possible pathophysiological mechanisms of altered motor rhythm in MCI are unclear. When investigating excitability mechanisms of M1 using TMS techniques, we found that motor thresholds, the I/O curve, and SICI were comparable in aMCI patients and HCs. These results confirm previous observations (Nardone et al., 2012, 2014; Tsutsumi et al., 2012) and support evidence of normal corticospinal excitability and normal intracortical excitability of M1 in aMCI patients. We also found comparable SAI between groups. Neurophysiological observations in HCs linked SAI to M1 cholinergic activity (Di Lazzaro et al., 2000; Tokimura et al., 2000; Ferreri et al., 2012), a measure that is altered in AD (Di Lazzaro et al., 2002; Guerra et al., 2011; Di Lorenzo et al., 2016; Bologna et al., 2020). Our results are consistent with previous studies in MCI and point to a preserved cholinergic inhibitory drive in M1 in the pre-dementia stage of AD (Sakuma et al., 2007; Di Lorenzo et al., 2020). The observation of normal M1 excitability parameters in aMCI patients imply that motor abnormalities in this condition are not related to M1 neurophysiological dysfunction. We also demonstrated weaker MEP facilitation at T2 after iTBS in aMCI patients as compared to HCs, which suggests altered LTP-like plasticity in M1. One recent study assessed iTBS-induced M1 plasticity in MCI patients and found that MCI patients showed impaired LTP-like aftereffects as compared to HCs (Di Lorenzo et al., 2020). In addition, the authors demonstrated that MCI patients who progressed to dementia at follow-up had weaker LTP-like plasticity at the time of first evaluation (Di Lorenzo et al., 2020). These data, along with our findings, further support altered LTP-like plasticity in M1 as a relevant pathophysiological process underlying AD and aMCI. These findings also confirm previous TMS and TMS-EEG studies demonstrating impaired M1 functionality in all stages of dementia (Ferreri et al., 2003, 2016; Julkunen et al., 2008; Guerra et al., 2015; Di Lorenzo et al., 2016; Trebbastoni et al., 2015). Amyloid beta and phosphorylated tau protein deposition are key neuropathological processes in AD (Hardy, 2002; Busche and Hyman, 2020) and are thought to underlie the disruption of synaptic plasticity mechanisms in this condition (Selkoe, 2008; Koch et al., 2011). Since aMCI is considered the predementia stage of AD (Petersen et al., 2014), we hypothesize that altered LTP-like plasticity in aMCI is due to early amyloid beta and phosphorylated tau protein deposition at the cortical level. However, we found that abnormal LTP-like plasticity in M1 did not correlate with altered movement rhythm in aMCI. This result is not surprising. Similar to what has been observed here in aMCI, we recently demonstrated a lack of correlation between




Fig. 1. MCI: mild cognitive impairment; HCs: healthy controls. Dots denote individual data. White diamonds denote average values. Horizontal lines indicate the median value (50th percentile). Boxes indicate the 25–75th percentiles of the dataset. Asterisks denote significant between-group differences at post hoc analyses.

these two neurophysiological abnormalities in AD patients (Bologna et al., 2020). Overall, these data suggest that altered movement rhythm is independent of M1 plasticity changes, and instead reflects other mechanisms. Thus, altered M1 plasticity does not necessarily constitute a pathophysiological substrate of motor impairment in these conditions. Instead, a recent study found that impaired LTP-like cortical plasticity in AD was selectively associated with less efficient verbal memory (Di Lorenzo et al., 2019).

An alternative explanation for motor impairment in aMCI is that less rhythmic movement during finger tapping reflects dysfunction in frontal areas, especially in relation to defective attentive processes (Rabinowitz and Lavner, 2014). In fact, performance of the finger-tapping task as regularly and precisely as possible requires a high level of attention, which may already be impaired in MCI

patients (Albert et al., 2011; McLaughlin et al., 2014; Kirova et al., 2015). The results of the present study support the hypothesized relationship between voluntary movement abnormalities and frontal lobe dysfunction by providing evidence of a negative correlation between movement rhythm and FAB score, i.e. the less rhythmic the movement, the greater the cognitive impairment in executive functions located in the frontal lobes (Dubois et al., 2000). Indeed, in patients with aMCI (Kume et al., 2011) or other conditions such as frontotemporal dementia (Guedj et al., 2008), FAB scores were found to correlate with SPECT perfusion in lateral and medial frontal areas. Moreover, even in the earliest stages of AD the pathological deposition of amyloid beta and phosphorylated tau protein is known to occur in the hippocampus as well as in other regions, including the frontal cortices (Okello et al.,

Table 2
Baseline cortical excitability measures.

	HCs	aMCI	p value
AMT	38.9 ± 4.1%	37.1 ± 5.4%	0.31
RMT	48.5 ± 8.0%	47.2 ± 11.3%	0.71
MT _{1mV}	70.1 ± 16.2%	66.1 ± 16.9%	0.51
Unconditioned MEPs (SICI protocol)	1.04 ± 0.49 mV	1.11 ± 0.52 mV	0.68
Unconditioned MEPs (SAI protocol)	1.00 ± 0.72 mV	1.01 ± 0.52 mV	0.96
MEP amplitude (T0)	0.87 ± 0.26 mV	0.99 ± 0.56 mV	0.35

aMCI = amnesic mild cognitive impairment; HCs = healthy controls; AMT = active motor threshold; RMT = resting motor threshold; MT_{1mV} = intensity required to produce motor evoked potentials of ~ 1 mV in size; MEPs = motor evoked potentials; SICI = short-interval intracortical inhibition; SAI = short-latency afferent inhibition; MEP amplitude (T0) = baseline MEP recording pre-intermittent theta burst stimulation. Values reflect mean ± 1 standard deviation.

2009; Chandra et al., 2019), which may underlie executive function impairment. Although not statistically significant, we also found a trend toward an association between MoCA scores and altered movement rhythm. This result is in line with other studies (Roalf et al., 2018; Suzumura et al., 2018) and may suggest that deficits in cognitive functions other than executive ones (e.g. memory) (Rabinowitz and Lavner, 2014) also contribute to finger tapping rhythm alterations. In summary, we may hypothesize that dysfunctions of brain areas involved in cognitive processes underlie the generation of altered motor rhythm in aMCI. This hypothesis, however, requires validation by further studies using structural and functional neuroimaging and molecular imaging.

In relation to the present results in aMCI patients, we have recently demonstrated that less rhythmic movement during finger tapping is combined with movement slowness in AD patients (Bologna et al., 2020). We also found that movement slowness in AD correlated with cholinergic M1 dysfunction (Bologna et al., 2020), a neurophysiological alteration that was not present in our aMCI cohort. Therefore, we now speculate that altered movement rhythm is the only motor abnormality occurring in the pre-dementia stage (aMCI), while altered movement rhythm occurring in combination with motor slowness occurs in clinically overt dementia as a result of a marked dysfunction in cholinergic neuro-

transmission in M1. Taken as a whole, the results of the present study in aMCI together with those of our previous study in AD (Bologna et al., 2020) suggest that voluntary movement, as assessed by kinematic techniques, may be an indirect biomarker of cognitive dysfunction within the aMCI and AD spectrum. Longitudinal studies are needed to elucidate whether kinematic methods may be used to predict the clinical course in MCI patients.

Our study has some limitations that must be considered. First, the sample size was relatively small, although the objective techniques used to quantify finger-tapping movements provided accurate and reproducible measurements of motor impairment (Heldman et al., 2011). Second, although we recruited aMCI patients based on accurate neuropsychological diagnoses and according to current clinical criteria (Albert et al., 2011), we acknowledge that we did not perform biomarker assessments (e.g. amyloid cerebrospinal fluid or positron emission tomography). Therefore, we cannot fully exclude that mild cognitive deficits in some patients of our sample were due to alternative aetiologies. However, since previous evidence has shown that aMCI patients have a higher probability of developing AD dementia than naMCI patients (Petersen, 2004; Winblad et al., 2004), we recruited only aMCI patients in our study in order to minimize the likelihood that cognitive impairment in MCI was due to types of dementia other than AD. Finally, in our assessment of M1 plasticity we did not use a neuronavigation system during TMS recording or collect more than 20 MEPs, methodological procedures that could have provided a more precise estimate of MEP amplitude as suggested by other studies (Chang et al., 2016; Goldsworthy et al., 2016).

In conclusion, our study provides new information on fine voluntary movement impairment in aMCI patients. In our patient sample, we found only less rhythmic movement, and no movement slowness. Altered movement rhythm was unrelated to changes in M1 excitability or LTP-like plasticity and was likely dependent on frontal area abnormalities. Our results suggest that altered rhythm in fine voluntary movements, as assessed by kinematic techniques, may be an early motor feature in patients with cognitive decline. Future longitudinal studies combining kinematic methods with TMS measures may provide a clearer understanding of the neurophysiological abnormalities that may predict the clinical course of MCI patients.




Fig. 2. Panel A. The input–output curve of motor evoked potentials (MEPs) in mild cognitive impairment (MCI) patients and healthy controls (HCs). The y-axis displays MEP amplitude (mV), while the x-axis displays the six tested stimulation intensities (80, 100, 120, 140, 160, and 180% of the resting motor threshold – RMT). Panel B. Short-interval intracortical inhibition (SICI) and short-latency afferent inhibition (SAI) in MCI patients and HCs. The y-axis provides the ratio between conditioned/unconditioned MEP amplitudes, while the x-axis shows the tested interstimulus intervals (2 and 4 ms for SICI, 22 and 24 ms for SAI). Panel C. Changes in MEP amplitude after the intermittent theta burst stimulation (iTBS) protocol in MCI patients and HCs. The y-axis displays MEP amplitudes normalized to baseline (T0), while the x-axis shows measurements at the four time points: before iTBS (T0) and 5 (T1), 15 (T2), and 30 min (T3) after iTBS. Asterisks denote significant between-group differences at post hoc analyses.




Fig. 3. Correlation between the rhythm of movement, as measured by the coefficient of variation (x-axis), and the Frontal Assessment Battery (FAB) score (y-axis).

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgements

The authors wish to thank all patients and healthy subjects for their participation in this research.

The authors also wish to thank Melissa Kerr (melissa.kerr@uniroma1.it) from the Department of Human Neurosciences, Sapienza University of Rome, for help in the English-language editing of the manuscript and Dr Davide Costa for help in the early phase of the study.

Funding sources for the study

None.

References

Aggarwal NT, Wilson RS, Beck TL, Bienias JL, Bennett DA. Motor dysfunction in mild cognitive impairment and the risk of incident Alzheimer disease. *Arch Neurol* 2006;63:1763–9.

Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement* 2011;7:270–9.

Antonini A, Abbruzzese G, Ferini-Strambi L, et al. Validation of the Italian version of the movement disorder society-unified Parkinson's disease rating scale. *Neurol Sci* 2013;34:683–7.

Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. *Arch Gen Psychiatry* 1961;4:561–71.

Berardelli A, Abbruzzese G, Chen R, Orth M, Ridding MC, Stinear C, et al. Consensus paper on short-interval intracortical inhibition and other transcranial magnetic stimulation intracortical paradigms in movement disorders. *Brain Stimul* 2010;3:183–91.

Bologna M, Guerra A, Colella D, Cioffi E, Paparella G, Di Vita A, et al. Bradykinesia in Alzheimer's disease and its neurophysiological substrates. *Clin Neurophysiol* 2020;131:850–8.

Bologna M, Guerra A, Paparella G, Giordo L, Alunni Fegatelli D, Vestri AR, et al. Neurophysiological correlates of bradykinesia in Parkinson's disease. *Brain* 2018;141:2432–44.

Bologna M, Leodori G, Stirpe P, Paparella G, Colella D, Belvisi D, et al. Bradykinesia in early and advanced Parkinson's disease. *J Neurol Sci* 2016;369:286–91.

Bologna M, Rocchi L, Paparella G, Nardella A, Li Voti P, Conte A, et al. Reversal of practice-related effects on corticospinal excitability has no immediate effect on behavioral outcome. *Brain Stimul* 2015;8:603–12.

Burns JM, Galvin JE, Roe CM, Morris JC, McKeel DW. The pathology of the substantia nigra in Alzheimer disease with extrapyramidal signs. *Neurology* 2005;64:1397–403.

Busche MA, Hyman BT. Synergy between amyloid- β and tau in Alzheimer's disease. *Nat Neurosci* 2020;23:1183–93.

Camarda R, Camarda C, Monastero R, Grimaldi S, Camarda LKC, Pipia C, et al. Movements execution in amnesic mild cognitive impairment and Alzheimer's disease. *Behav Neurol* 2007;18:135–42.

Cantone M, Di Pino G, Capone F, Piombo M, Chiarello D, Cheeran B, et al. The contribution of transcranial magnetic stimulation in the diagnosis and in the management of dementia. *Clin Neurophysiol* 2014;125:1509–32.

Chandra A, Valkimadi P, Pagano G, Cousins O, Dervenoulas G, Politis M, et al. Applications of amyloid, tau, and neuroinflammation PET imaging to Alzheimer's disease and mild cognitive impairment. *Hum Brain Mapp* 2019;40:5424–42.

Chang WH, Fried PJ, Saxena S, Jannati A, Gomes-Osman J, Kim Y-H, et al. Optimal number of pulses as outcome measures of neuronavigated transcranial magnetic stimulation. *Clin Neurophysiol* 2016;127:2892–7.

Curra A, Modugno N, Inghilleri M, Manfredi M, Hallett M, Berardelli A. Transcranial magnetic stimulation techniques in clinical investigation. *Neurology* 2002;59:1851–9.

Di Lazzaro V, Oliviero A, Profice P, Pennisi MA, Di Giovanni S, Zito G, et al. Muscarinic receptor blockade has differential effects on the excitability of intracortical circuits in the human motor cortex. *Exp Brain Res* 2000;135:455–61.

Di Lazzaro V, Oliviero A, Tonali PA, Marra C, Daniele A, Profice P, et al. Noninvasive in vivo assessment of cholinergic cortical circuits in AD using transcranial magnetic stimulation. *Neurology* 2002;59:392–7.

Di Lorenzo F, Motta C, Bonni S, Mercuri NB, Caltagirone C, Martorana A, et al. LTP-like cortical plasticity is associated with verbal memory impairment in Alzheimer's disease patients. *Brain Stimul* 2019;12:148–51.

Di Lorenzo F, Motta C, Casula EP, Bonni S, Assogna M, Caltagirone C, et al. LTP-like cortical plasticity predicts conversion to dementia in patients with memory impairment. *Brain Stimul* 2020;13:1175–82.

Di Lorenzo F, Ponso V, Bonni S, Motta C, Negrão Serra PC, Bozzali M, et al. Long-term potentiation-like cortical plasticity is disrupted in Alzheimer's disease patients independently from age of onset: Cortical Plasticity in Alzheimer's Disease. *Ann Neurol* 2016;80:202–10.

Dubois B, Slachevsky A, Litvan I, Pillon B. The FAB: a frontal assessment battery at bedside. *Neurology* 2000;55:1621–6.

Espay AJ, Beaton DE, Morgante F, Gunraj CA, Lang AE, Chen R. Impairments of speed and amplitude of movement in Parkinson's disease: a pilot study. *Mov Disord* 2009;24:1001–8.

Espay AJ, Giuffrida JP, Chen R, Payne M, Mazzella F, Dunn E, et al. Differential response of speed, amplitude, and rhythm to dopaminergic medications in Parkinson's disease. *Mov Disord* 2011;26:2504–8.

Ferreri F, Pauri F, Pasqualetti P, Fini R, Dal Forno G, Rossini PM. Motor cortex excitability in Alzheimer's disease: A transcranial magnetic stimulation study. *Ann Neurol* 2003;53:102–8.

Ferreri F, Ponso D, Hukkanen T, Mervaala E, Könönen M, Pasqualetti P, et al. Human brain cortical correlates of short-latency afferent inhibition: a combined EEG–TMS study. *J Neurophysiol* 2012;108:314–23.

Ferreri F, Vecchio F, Vollero L, Guerra A, Petrichella S, Ponso D, et al. Sensorimotor cortex excitability and connectivity in Alzheimer's disease: A TMS–EEG Co-registration study: Sensorimotor cortex excitability and connectivity in AD. *Hum Brain Mapp* 2016;37:2083–96.

Freitas S, Simões MR, Alves L, Santana I. Montreal cognitive assessment: validation study for mild cognitive impairment and Alzheimer disease. *Alzheimer Dis Assoc Disord* 2013;27:37–43.

Goldman WP, Baty JD, Buckles VD, Sahrman S, Morris JC. Motor dysfunction in mildly demented AD individuals without extrapyramidal signs. *Neurology* 1999;53:956–956.

Goldworthy MR, Hordacre B, Ridding MC. Minimum number of trials required for within- and between-session reliability of TMS measures of corticospinal excitability. *Neuroscience* 2016;320:205–9.

Guedj E, Allali G, Goetz C, Le Ber I, Volteau M, Lacomblez L, et al. Frontal Assessment Battery is a marker of dorsolateral and medial frontal functions: A SPECT study in frontotemporal dementia. *J Neurol Sci* 2008;273:84–7.

Guerra A, Assenza F, Bressi F, Scarscia F, Del Duca M, Ursini F, et al. Transcranial magnetic stimulation studies in Alzheimer's disease. *Int J Alzheimers Dis* 2011;2011:1–9.

Guerra A, Petrichella S, Vollero L, Ponso D, Pasqualetti P, Määttä S, et al. Neurophysiological features of motor cortex excitability and plasticity in Subcortical Ischemic Vascular Dementia: A TMS mapping study. *Clin Neurophysiol* 2015;126:906–13.

Hardy J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. *Science* 2002;297:353–6.

Heldman DA, Giuffrida JP, Chen R, Payne M, Mazzella F, Duker AP, et al. The modified bradykinesia rating scale for Parkinson's disease: reliability and comparison with kinematic measures. *Mov Disord* 2011;26:1859–63.

Huang Y-Z, Edwards MJ, Rounis E, Bhatia KP, Rothwell JC. Theta burst stimulation of the human motor cortex. *Neuron* 2005;45:201–6.

- Iansek R, Huxham F, McGinley J. The sequence effect and gait festination in Parkinson disease: contributors to freezing of gait?. *Mov Disord* 2006;21:1419–24.
- Julkunen P, Jauhainen AM, Westerén-Punnonen S, Pirinen E, Soininen H, Könönen M, et al. Navigated TMS combined with EEG in mild cognitive impairment and Alzheimer's disease: A pilot study. *J Neurosci Methods* 2008;172:270–6.
- Kirova A-M, Bays RB, Lagalwar S. Working memory and executive function decline across normal aging, mild cognitive impairment, and Alzheimer's disease. *Biomed Res Int* 2015;2015:748212.
- Kluger A, Gianutsos JG, Golomb J, Ferris SH, George AE, Franssen E, et al. Patterns of motor impairment in normal aging, mild cognitive decline, and early Alzheimer's disease. *J Gerontol B Psychol Sci Soc Sci* 1997;52B:P28–39.
- Koch G, Esposito Z, Kusayanagi H, Monteleone F, Codecá C, Di Lorenzo F, et al. CSF tau levels influence cortical plasticity in Alzheimer's disease patients. *J Alzheimers Dis* 2011;26:181–6.
- Kujirai T, Caramia MD, Rothwell JC, Day BL, Thompson PD, Ferbert A, et al. Corticocortical inhibition in human motor cortex. *J Physiol* 1993;471:501–19.
- Kume K, Hanyu H, Murakami M, Sato T, Hirao K, Kanetaka H, et al. Frontal Assessment Battery and brain perfusion images in amnesic mild cognitive impairment: Frontal Assessment Battery and brain perfusion. *Geriatr Gerontol Int* 2011;11:77–82.
- Louis ED, Schupf N, Manly J, Marder K, Tang MX, Mayeux R. Association between mild parkinsonian signs and mild cognitive impairment in a community. *Neurology* 2005;64:1157–61.
- McLaughlin PM, Anderson ND, Rich JB, Chertkow H, Murtha SJE. Visual selective attention in amnesic mild cognitive impairment. *J Gerontol B Psychol Sci Soc Sci* 2014;69:881–91.
- Möller C, Arai N, Lücke J, Ziemann U. Hysteresis effects on the input-output curve of motor evoked potentials. *Clin Neurophysiol* 2009;120:1003–8.
- Nardone R, Bergmann J, Christova M, Caleri F, Tezzon F, Ladurner G, et al. Short latency afferent inhibition differs among the subtypes of mild cognitive impairment. *J Neural Transm* 2012;119:463–71.
- Nardone R, Tezzon F, Höller Y, Golaszewski S, Trinka E, Brigo F. Transcranial magnetic stimulation (TMS)/repetitive TMS in mild cognitive impairment and Alzheimer's disease. *Acta Neurol Scand* 2014;129:351–66.
- Nitrini R, Buchpiguel CA, Caramelli P, Bahia VS, Mathias SC, Nascimento CMR, et al. SPECT in Alzheimer's disease: features associated with bilateral parietotemporal hypoperfusion. *Acta Neurol Scand* 2000;101:172–6.
- Okello A, Edison P, Archer HA, Turkheimer FE, Kennedy J, Bullock R, et al. Microglial activation and amyloid deposition in mild cognitive impairment: a PET study. *Neurology* 2009;72:56–62.
- Olazarán J, Prieto J, Cruz I, Esteban A. Cortical excitability in very mild Alzheimer's disease: a long-term follow-up study. *J Neurol* 2010;257:2078–85.
- Oldfield RC. The assessment and analysis of handedness: the Edinburgh inventory. *Neuropsychologia* 1971;9:97–113.
- Orta-Salazar E, Feria-Velasco AI, Díaz-Cintra S. Primary motor cortex alterations in Alzheimer disease: a study in the 3xTg-AD model. *Neurología* 2019;34:429–36.
- Padovani A, Benussi A, Cantoni V, Dell'Era V, Cotelli MS, Caratozzolo S, et al. Diagnosis of mild cognitive impairment due to Alzheimer's disease with transcranial magnetic stimulation. *J Alzheimers Dis* 2018;65:221–30.
- Padovani A, Benussi A, Cotelli MS, Ferrari C, Cantoni V, Dell'Era V, et al. Transcranial magnetic stimulation and amyloid markers in mild cognitive impairment: impact on diagnostic confidence and diagnostic accuracy. *Alzheimers Res Ther* 2019;11:95.
- Petersen RC. Mild cognitive impairment as a diagnostic entity. *J Intern Med* 2004;256:183–94.
- Petersen RC, Caracciolo B, Brayne C, Gauthier S, Jelic V, Fratiglioni L. Mild cognitive impairment: a concept in evolution. *J Intern Med* 2014;275:214–28.
- Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, et al. MDS clinical diagnostic criteria for Parkinson's disease. *Mov Disord* 2015;30:1591–601.
- Rabinowitz I, Lavner Y. Association between finger tapping, attention, memory, and cognitive diagnosis in elderly patients. *Percept Mot Skills* 2014;119:259–78.
- Roalf DR, Rupert P, Mechanic-Hamilton D, Brennan L, Duda JE, Weintraub D, et al. Quantitative assessment of finger tapping characteristics in mild cognitive impairment, Alzheimer's disease, and Parkinson's disease. *J Neurol* 2018;265:1365–75.
- Rossi S, Hallett M, Rossini PM, Pascual-Leone A. Safety of TMS Consensus Group. Safety, ethical considerations, and application guidelines for the use of transcranial magnetic stimulation in clinical practice and research. *Clin Neurophysiol* 2009;120:2008–39.
- Rossini PM, Burke D, Chen R, Cohen LG, Daskalakis Z, Di Iorio R, et al. Non-invasive electrical and magnetic stimulation of the brain, spinal cord, roots and peripheral nerves: Basic principles and procedures for routine clinical and research application. An updated report from an I.F.C.N. Committee *Clin Neurophysiol* 2015;126:1071–107.
- Sakuma K, Murakami T, Nakashima K. Short latency afferent inhibition is not impaired in mild cognitive impairment. *Clin Neurophysiol* 2007;118:1460–3.
- Schröter A, Mergl R, Bürger K, Hampel H, Möller H-J, Hegerl U. Kinematic analysis of handwriting movements in patients with Alzheimer's disease, mild cognitive impairment, depression and healthy subjects. *Dement Geriatr Cogn Disord* 2003;15:132–42.
- Selkoe DJ. Soluble oligomers of the amyloid β -protein impair synaptic plasticity and behavior. *Behav Brain Res* 2008;192:106–13.
- Suzumura S, Osawa A, Maeda N, Sano Y, Kandori A, Mizuguchi T, et al. Differences among patients with Alzheimer's disease, older adults with mild cognitive impairment and healthy older adults in finger dexterity. *Geriatr Gerontol Int* 2018;18:907–14.
- Tokimura H, Di Lazzaro V, Tokimura Y, Oliviero A, Profice P, Insola A, et al. Short latency inhibition of human hand motor cortex by somatosensory input from the hand. *J Physiol* 2000;523:503–13.
- Trebbastoni A, Pichiorri F, D'Antonio F, Campanelli A, Onesti E, Ceccanti M, et al. Altered cortical synaptic plasticity in response to 5-Hz repetitive transcranial magnetic stimulation as a new electrophysiological finding in amnesic mild cognitive impairment converting to Alzheimer's disease: results from a 4-year prospective cohort study. *Front Aging Neurosci* 2015;7:253.
- Tsutsumi R, Hanajima R, Hamada M, Shirota Y, Matsumoto H, Terao Y, et al. Reduced interhemispheric inhibition in mild cognitive impairment. *Exp Brain Res* 2012;218:21–6.
- Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund L-O, et al. Mild cognitive impairment—beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. *J Intern Med* 2004;256:240–6.
- Yan JH, Rountree S, Massman P, Doody RS, Li H. Alzheimer's disease and mild cognitive impairment deteriorate fine movement control. *J Psychiatr Res* 2008;42:1203–12.
- Zhang L, Zhao Y, Shen C, Lei L, Dong J, Zou D, et al. Can long-term regular practice of physical exercises including taichi improve finger tapping of patients presenting with mild cognitive impairment?. *Front Physiol* 2018;9:1396.
- Ziemann U, Reis J, Schwenkreis P, Rosanova M, Strafella A, Badawy R, et al. TMS and drugs revisited 2014. *Clin Neurophysiol* 2015;126:1847–68.